HUYABIO International is the lead sponsor of 4 current clinical trials in our USA and UK registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 1. The drugs named most often in its trials are Chidamide and Nivolumab. The most-studied condition is Non Small Cell Lung Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
NCT04680026 · Atrial Fibrillation
|
Phase 2 | Active, closed | 2021-06 | USA |
|
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
|
Phase 3 | Active, closed | 2021-08 | UK, USA |
|
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer
|
Phase 1 | Active, closed | 2021-12 | USA |
|
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974 · ClinicalTrials.gov ↗ · Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
|
Phase 1 | Active, closed | 2022-08 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 0 |
| Clinical trials in UK | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
HUYABIO International is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of its 4 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Chidamide (1) and Nivolumab (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.